Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Renal Drug Handbook, fifth edition - Alogliptin tablets (single agent)
Product / population
Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source revision
Fifth edition, 2019
Retrieved
2026-09-05
Local review status
Historical source, separately displayed. Renal tables were read with page-image inspection.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
NESINA: single-agent renal dosing is not combination eligibility
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
What to reconcile: Check every component and the dialysis modality before applying the single-agent schedule.
Renal Drug Handbook, fifth edition - Alogliptin tablets (single agent)
UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.
Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods. Source date: Fifth edition, 2019 Retrieved: 2026-09-05
Historical source, separately displayed. Renal tables were read with page-image inspection.
Historical renal and dialysis observations
The book gives 12.5 mg/day at 30-50 mL/min and 6.25 mg/day in its 10-30 and below-10 bands. It notes approximately 7% removal during a 3-hour hemodialysis session despite broadly describing limited dialysis removal.
RDM31-alogliptin-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information
Source-specific limits
The historical bands overlap at 30 and do not cover the label's full 30-to-less-than-60 band. Use the selected source's complete boundaries, not a hybrid table.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 44; PDF page(s) 63
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.